Surgery for Pancreatic Neuroendocrine Tumor G3 and Carcinoma G3 Should be Considered Separately

Tsukasa Yoshida,Susumu Hijioka,Waki Hosoda,Makoto Ueno,Masayuki Furukawa,Noritoshi Kobayashi,Masafumi Ikeda,Tetsuhide Ito,Yuzo Kodama,Chigusa Morizane,Kenji Notohara,Hiroki Taguchi,Masayuki Kitano,Kei Yane,Yoshiaki Tsuchiya,Izumi Komoto,Hiroki Tanaka,Akihito Tsuji,Syunpei Hashigo,Tetsuya Mine,Atsushi Kanno,Go Murohisa,Katsuyuki Miyabe,Tadayuki Takagi,Nobutaka Matayoshi,Masafumi Sakaguchi,Hiroshi Ishii,Yasushi Kojima,Keitaro Matsuo,Hideyuki Yoshitomi,Shoji Nakamori,Hiroaki Yanagimoto,Yasushi Yatabe,Junji Furuse,Nobumasa Mizuno

Surgery for Pancreatic Neuroendocrine Tumor G3 and Carcinoma G3 Should be Considered Separately

2019

Background The role of surgery in pancreatic neuroendocrine neoplasm grade 3 (pNEN-G3) treatment remains unclear. We aimed to clarify the role of surgery for pNEN-G3, which has recently been reclassified as pancreatic neuroendocrine tumor-G3 (pNET-G3) and pancreatic neuroendocrine carcinoma-G3 (pNEC-G3), with and without metastases, respectively.

Keywords:

Pancreatic neuroendocrine tumor
Pathology
Carcinoma
Pancreatic Neuroendocrine Neoplasm
Surgery
Medicine
overall survival
Surgical oncology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations